Baozhong Yu

Baozhong Yu

Auto-generated profile, based on publicly available information

Baozhong Yu

Emergency Medicine Clinical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, & Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation, Clinical Center for Medicine in Acute Infection, Capital Medical University, Beijing, People's Republic of China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2022 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
BYBaozhong Yu
Baozhong Yu
MCMaolin Chen
Maolin Chen
YZYe Zhang
Ye Zhang
YCYudan Cao
Yudan Cao
JYJun Yang
Jun Yang
JWJUNYU WANG
JUNYU WANG
Purpose: The objective of this study was to explore the diagnostic and prognostic value of interleukin-6 (IL-6) in sepsis patients presenting to the emergency department. Patients and Methods: A total of 128 patients who visited the emergency department of West Hospital of Beijing Chaoyang Hospital, affiliated to Capital Medical University, from November 2021 to February 2022 were subjected to this study. According to Sepsis-3.0 diagnostic criteria for sepsis, patients were divided into non-sepsis group (65 cases) and sepsis group (63 cases). Demographic data and clinical characteristics of the two patient groups were compared. Serum levels of biomarkers including IL-6, blood urea nitrogen (BUN), and lactic acid (Lac) were compared with Sequential Organ Failure Assessment (SOFA) and Glasgow Coma Scale (GCS) scores. Logistic regression was used to analyze independent risk factors and Receiver Operating Characteristic Curve (ROC) method was used to analyze the Area Under the Curve (AUC) to determine the diagnostic and prognostic value of markers. Results: Compared with non-sepsis patients, levels of IL-6, PCT, CRP and BUN were significantly higher in sepsis patients (10.84 (4.41– 27.01): 92.22 (21.53– 201.12), 0.03 (0.01– 0.1):0.49 (0.08– 3.1), 8.3 (0.5– 31.8):39.8(10.3– 98.6), 7.01 (4.90– 11.74):13.03 (6.93– 25.99), all p = 0.001). IL-6, BUN and mean arterial pressure (MAP) were independent risk factors for sepsis diagnosis. AUC values of IL-6, BUN, MAP and IL-6+BUN+MAP were 0.764, 0.696, 0.685, and 0.848, respectively. Lactate, age and SOFA score were independent risk factors for 28-day mortality in sepsis patients. The AUC of Lac, age, SOFA score and Lac+age+SOFA score to predict 28-day death in sepsis patients was 0.679, 0.626, 0.747, and 0.819, respectively. Conclusion: IL-6 is an independent predictor of sepsis diagnosis, and the combination of blood BUN and MAP has superior diagnostic performance. Lac, age, and SOFA score could effectively predict clinical outcomes in patients with sepsis.

25 January 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BYBaozhong Yu
Baozhong Yu
XZXiang Zheng
Xiang Zheng
ZSZejia Sun
Zejia Sun
PCPeng Cao
Peng Cao
JZJiandong Zhang
Jiandong Zhang
WWWei Wang
Wei Wang
Purpose: Alpha-adrenergic receptor blockers can be effectively used in the context of medical expulsion therapy (MET) to treat ureteric stones. This study was designed to evaluate the safety and efficacy of doxazosin in MET relative to placebo or tamsulosin. Methods: We systematically searched the PubMed, the Cochrane Library, EMBASE, Chinese Academic Database, and Web of Science databases to select randomized controlled trials (RCT) that compared the use of doxazosin with placebo or tamsulosin to treat ureteric stones. All patients we included were limited to those diagnosed with visible stones in the distal ureter. The diameter of ureteric stones does not exceed 10 mm. Results: Eight trials comparing doxazosin with placebo or tamsulosin containing 667 patients were assessed in the final analysis. The meta-analysis showed that doxazosin effectively treated ureteric stones and was better than placebo in terms of efficacy. Relative to the placebo group, the expulsion rate of stones from the distal ureter (OR = 3.00, 95% CI [2.15, 4.19], I2 = 0%, P < 0.00001) was significantly increased, and the expulsion time (days) was shortened (mean difference) (MD) = −4.03, 95% CI [−4.53, −3.53], P < 0.00001). The doxazosin group experienced fewer pain episodes (MD = −0.78, CI = [−0.94, −0.23], I2 = 0%, P < 0.00001) than the placebo group. A subgroup analysis showed that the doxazosin group had a higher expulsion rate (of 5–10 mm stones) compared with the placebo group. Although doxazosin resulted in significantly more adverse effects compared with the placebo, the patient’s symptoms were mild and no further medical interventions were required. Moreover, the expulsion time (days) was shorter for patients receiving doxazosin (MD = −0.61, 95% CI [−0.97, −0.24], I2 = 39%, P = 0.001) than those receiving tamsulosin. Conclusion: Compared with the placebo group, patients receiving doxazosin had a greater expulsion rate, a reduced expulsion time, and fewer pain episodes. The expulsion time of doxazosin was shorter than that of tamsulosin.

28 February 2020 in Research Square
Verified
Preprint
Open access
PDF file
BYBao Zhong Yu
Bao Zhong Yu
JZJian Dong Zhang
Jian Dong Zhang
ZSZe Jia Sun
Ze Jia Sun
PCPeng Cao
Peng Cao
XZXiang Zheng
Xiang Zheng
WWWei Wang
Wei Wang
Background: Renal cell carcinoma is one of the most common and lethal types of cancer within the urinary system. the current challenges include how to diagnose RCC in the earlier stage and the drug resistance to chemotherapy or radiotherapy. Therefore, to investigate the survival rate and immune infiltration in RCC base on gene expression of IFI16 in RCC. Methods: We explored the relationship between the transcription level of IFI16 and clinical data in RCC through various online databases, including ONCOMINE, GEPIA, Timer and COEXPEDIA. Results: In comparison with the corresponding normal tissues, the mRNA expression levels of IFI16 are higher in KIRC tissues (p< 0.05), while lower in KICH tissues (p<0.05). The mRNA expression of IFI16 has a positive correlation with TNM stage in KIRC(p=8.56e-07) and KIRP(p=0.00078). In KIRC, the higher expression of IFI16 suggests lower OS(HR=1.4; P=0.037; Log-rank p=0.037). In KIRP, the higher expression of IFI16 suggests lower DFS and OS (respectively, HR=1.9, P=0.037, Log-rank p=0.034; HR=2.3, P=0.011, Log-rank p=0.0091). In contrast, the expression level of IFI16 has a negative correlation with the tumour purity in KICH, KIRC and KIRP via the Timer database (all, p < 0.05). In KIRC and KIRP, the expression level of IFI16 has a positive correlation with the tumor-infiltrating immune cells (TIICs) (all, p < 0.05), except the macrophages in KIRP. In KIRC, the main TIICs in the arm-level deletion state of the IFI16 gene were B cell, CD4+T cell, Neutrophil, and Dendritic cell, while the main TIICs in the high amplification state were Macrophage (all, p < 0.0001). 108 genes are co-expressed with the IFI16 gene. Function enrichment analysis by GO and KEGG mainly enriched on some functions, including neutrophil degranulation, phagocytosis, vesicle-mediated transport regulation and enriched on some signal pathways, including tuberculosis, toxoplasmosis, phagosome, leishmaniasis, and Fc gamma R-med8ted. Conclusions: IFI16 acts as an oncogene in the progression of kidney cancer which is overexpressed in the RCC tissues. Apart from that, IFI16 has been determined as a marker of diagnosis and prognosis in RCC, which might be associated with the immune infiltration.